

Marco Lobba, PhD, is the CEO and co-founder of Catena Biosciences which is focused on developing transformative protein and cell-based therapies using patented coupling technology. Marco received his Ph.D. in 2020 from UC Berkeley where he worked jointly between the labs of Prof. Matt Francis and Prof. Jennifer Doudna on protein modification approaches to CRISPR/Cas9 delivery. Prior to his Ph.D. Marco worked as the Quality Manager for Anresco Laboratories, and received his undergraduate degree from Pomona College.